- Conditions
- Lung Cancer
- Interventions
- carboplatin, paclitaxel
- Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 584 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2006
- U.S. locations
- 35
- States / cities
- La Jolla, California • San Francisco, California • Wilmington, Delaware + 24 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 745–768
of 17,832
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Prostate Cancer
- Interventions
- bicalutamide, radiation therapy, placebo
- Drug · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- Male only
- Enrollment
- 840 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2022
- U.S. locations
- 221
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 168 more
- Conditions
- Estrogen Receptor Negative (ER-Negative) Breast Cancer, Progesterone Receptor Negative (PR-Negative) Breast Cancer, Human Epidermal Growth Factor Receptor 2 Negative (HER2-Negative) Breast Cancer, Brain Metastases
- Interventions
- INIPARIB + irinotecan
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 10 more
- Conditions
- Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Plasma Cell Neoplasm
- Interventions
- Siltuximab
- Biological
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Dallas, Texas • Houston, Texas
- Conditions
- Celiac Disease
- Interventions
- Cohort 1 in Part A, Cohort 2 in Part A, Placebo: Group 1 in Part B and Part C, Group 2 in Part B and Part C, Group 3 in Part B and Part C, Group 4 in Part B and Part C
- Drug · Other
- Lead sponsor
- Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 128 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Anaheim, California • St. Petersburg, Florida + 20 more
- Conditions
- Hypertension
- Interventions
- Azilsartan Medoxomil, Valsartan
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 984 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 77
- States / cities
- Huntsville, Alabama • Glendale, Arizona • Phoenix, Arizona + 74 more
- Conditions
- Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy
- Interventions
- Not listed
- Lead sponsor
- Wayne State University
- Other
- Eligibility
- Up to 20 Years
- Enrollment
- 288 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 12
- States / cities
- Aurora, Colorado • Chicago, Illinois • Boston, Massachusetts + 9 more
- Conditions
- Respiratory Syncytial Virus (RSV)
- Interventions
- Presatovir, Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 17
- States / cities
- Phoenix, Arizona • Los Angeles, California • San Francisco, California + 14 more
- Conditions
- Choroidal Melanoma, Indeterminate Lesions, Uveal Melanoma, Ocular Melanoma
- Interventions
- Bel-sar, Suprachoroidal Microinjector, Infrared Laser, Sham Infrared Laser, Sham Microinjector
- Drug · Device
- Lead sponsor
- Aura Biosciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 25
- States / cities
- Los Angeles, California • Palo Alto, California • Sacramento, California + 20 more
- Conditions
- Locally Advanced Bone Sarcoma, Locally Advanced Dedifferentiated Liposarcoma, Locally Advanced Gastrointestinal Stromal Tumor, Locally Advanced Soft Tissue Sarcoma, Metastatic Bone Sarcoma, Metastatic Liposarcoma, Metastatic Soft Tissue Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Metastatic Unresectable Sarcoma, Pleomorphic Liposarcoma, Stage III Bone Sarcoma AJCC v7, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Bone Sarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Stage IVA Bone Sarcoma AJCC v7, Stage IVB Bone Sarcoma AJCC v7, Unresectable Bone Sarcoma, Unresectable Dedifferentiated Liposarcoma, Unresectable Liposarcoma, Unresectable Malignant Gastrointestinal Stromal Tumor, Unresectable Soft Tissue Sarcoma
- Interventions
- Ipilimumab, Laboratory Biomarker Analysis, Nivolumab, Quality-of-Life Assessment
- Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 651
- States / cities
- Anchorage, Alaska • Hot Springs, Arkansas • Little Rock, Arkansas + 402 more
- Conditions
- Coronavirus Disease 2019 (COVID-19)
- Interventions
- AZD7442 (tixagevimab [AZD8895] + cilgavimab [AZD1061])
- Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 251 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Modesto, California • Westminster, California + 13 more
- Conditions
- Breast Cancer, Metastatic Breast Cancer
- Interventions
- Elacestrant, Alpelisib, Everolimus, Ribociclib, Palbociclib, Capivasertib, Abemaciclib
- Drug
- Lead sponsor
- Stemline Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 435 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 35
- States / cities
- Dothan, Alabama • Phoenix, Arizona • Springdale, Arkansas + 30 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Lixisenatide (AVE0010), Lixisenatide Placebo, Pen auto-injector, Sitagliptin, Sitagliptin Placebo, Metformin
- Drug · Device
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 319 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 21
- States / cities
- Montgomery, Alabama • Muscle Shoals, Alabama • Mesa, Arizona + 17 more
- Conditions
- Influenza
- Interventions
- Peramivir, Placebo Comparator
- Drug
- Lead sponsor
- BioCryst Pharmaceuticals
- Industry
- Eligibility
- 12 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 96
- States / cities
- Birmingham, Alabama • Hot Springs, Arkansas • Jonesboro, Arkansas + 93 more
- Conditions
- Melanoma
- Interventions
- glembatumumab vedotin, glembatumumab vedotin and varlilumab, glembatumumab vedotin and PD-1 targeted checkpoint inhibitor (nivolumab OR pembrolizumab), glembatumumab vedotin and CDX-301
- Drug
- Lead sponsor
- Celldex Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 14
- States / cities
- Los Angeles, California • San Francisco, California • Fort Myers, Florida + 10 more
- Conditions
- Infectious Disease
- Interventions
- Start Antibiotics / Continue Antibiotics for treatment of bacteriuria, No Antibiotics for treatment of bacteriuria
- Drug · Other
- Lead sponsor
- Mount Sinai Hospital, Canada
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 550 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Achondroplasia
- Interventions
- BMN 111
- Drug
- Lead sponsor
- BioMarin Pharmaceutical
- Industry
- Eligibility
- 5 Years to 14 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 6
- States / cities
- Oakland, California • Torrance, California • Chicago, Illinois + 3 more
- Conditions
- Prostate Cancer Metastatic
- Interventions
- ARV-110
- Drug
- Lead sponsor
- Arvinas Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 248 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 54
- States / cities
- Los Angeles, California • Orange, California • San Francisco, California + 51 more
- Conditions
- Metastatic Cholangiocarcinoma, Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Unresectable Cholangiocarcinoma, Unresectable Hepatocellular Carcinoma, Unresectable Intrahepatic Cholangiocarcinoma
- Interventions
- Carboplatin, Paclitaxel, Pevonedistat
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 419
- States / cities
- Anchorage, Alaska • Kingman, Arizona • Phoenix, Arizona + 254 more
- Conditions
- Scoliosis
- Interventions
- Surgical intervention, Non-operative intervention
- Procedure · Other
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 286 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 7
- States / cities
- Chicago, Illinois • Louisville, Kentucky • Baltimore, Maryland + 3 more
- Conditions
- Sleep Restriction
- Interventions
- Sleep restriction
- Other
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Hiv, Chlamydia, Gonorrhea, Relation, Interpersonal
- Interventions
- 2GETHER, Positive Affect Enhancement
- Behavioral
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 256 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Heart Failure
- Interventions
- Inter-Atrial Shunt Device, Intracardiac Echo
- Device · Other
- Lead sponsor
- Corvia Medical
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2026
- U.S. locations
- 17
- States / cities
- Tucson, Arizona • New Haven, Connecticut • Chicago, Illinois + 11 more
- Conditions
- Osteoarthritis, Knee Pain
- Interventions
- SL-1002, Placebo
- Drug
- Lead sponsor
- Saol Therapeutics Inc
- Industry
- Eligibility
- 35 Years and older
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 15
- States / cities
- Greenwood Village, Colorado • Washington D.C., District of Columbia • Coral Gables, Florida + 12 more